Trials / Unknown
UnknownNCT04018131
The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy
The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy, a Study of Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ Serum Levels
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- Sponsor
- Fakultas Kedokteran Universitas Indonesia · Academic / Other
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory mediator including Interleukin-4, Interleukin-12, and Interferon-Ɣ. Recent treatment of atopic dermatitis mainly focused on reducing the inflammation through topical and systemic regiments. However, no systemic medication could control the atopic dermatitis remission yet, and the current immunosuppressive agent used may cause many side effects if administered on a long term basis. In the future, treatment of atopic dermatitis were specifically targeted to inhibit the role of Th2. Cimetidine is H2 receptor antihistamine that has been widely used as gastrointestinal medication for a long time. Cimetidine could modulate the immune system by activating the Th1 and lowering the Th2 activity, and lowering the IgE levels thus reducing the severity of atopic dermatitis.
Detailed description
The aim of this study is to measure the efficacy of cimetidine for acute, extrinsic-atopic dermatitis treated with standard therapy using SCORAD as the clinical outcome. This study also measure Immunoglobulin E, Interleukin-4, Interleukin-12, and Interferon-Ɣ serum levels before and after treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cimetidine | Antihistamine 2 antagonist |
| DRUG | Placebos | Placebo drug |
Timeline
- Start date
- 2018-03-26
- Primary completion
- 2020-03-30
- Completion
- 2020-06-30
- First posted
- 2019-07-12
- Last updated
- 2019-10-04
Locations
1 site across 1 country: Indonesia
Source: ClinicalTrials.gov record NCT04018131. Inclusion in this directory is not an endorsement.